Iovance Biotherapeutics (IOVA) Total Liabilities: 2010-2025
Historic Total Liabilities for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $202.7 million.
- Iovance Biotherapeutics' Total Liabilities rose 126.20% to $202.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.7 million, marking a year-over-year increase of 126.20%. This contributed to the annual value of $200.0 million for FY2024, which is 2.19% up from last year.
- Latest data reveals that Iovance Biotherapeutics reported Total Liabilities of $202.7 million as of Q3 2025, which was down 3.01% from $208.9 million recorded in Q2 2025.
- Over the past 5 years, Iovance Biotherapeutics' Total Liabilities peaked at $208.9 million during Q2 2025, and registered a low of -$773.5 million during Q3 2024.
- Over the past 3 years, Iovance Biotherapeutics' median Total Liabilities value was $189.8 million (recorded in 2024), while the average stood at $15.4 million.
- As far as peak fluctuations go, Iovance Biotherapeutics' Total Liabilities tumbled by 533.78% in 2024, and later spiked by 127.19% in 2025.
- Iovance Biotherapeutics' Total Liabilities (Quarterly) stood at $195.7 million in 2023, then increased by 2.19% to $200.0 million in 2024, then skyrocketed by 126.20% to $202.7 million in 2025.
- Its Total Liabilities was $202.7 million in Q3 2025, compared to $208.9 million in Q2 2025 and $198.9 million in Q1 2025.